

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: T. BARBERICH et al.

Application No.: 09/527,844

Filed: March 17, 2000

METHODS AND COMPOSITIONS FOR For:

THE TREATMENT OF NEUROLEPTIC AND RELATED DISORDERS USING ZIPRASIDONE METABOLITES

Group Art Unit: 1617

Examiner: M. Bahar

Attorney Docket No.: 4821-334-999

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This is in response to the Office Action dated June 25, 2001 in which the application was examined for restriction purposes only. Applicants respectfully request entry of the following remarks and provisional election. Enclosed herewith is a Petition for Extension of Time with provision for the required fee.

REMARKS

The Examiner required that this application be restricted to one of the following groups of claims: Group I (claims 1-15); Group II (claims 16-45); Group III (claims 46-47); or Group IV (claims 48-49). Applicants provisionally elect, with traverse, Group I (claims 1-15), which are directed, in part, to a method of treating or preventing a disorder ameliorated by the inhibition of serotonin reuptake at 5-HT₂ receptors and/or inhibition of dopamine reuptake at dopamine D2 receptors which comprises administering to a patient in need of such treatment a therapeutically effective amount of a ziprasidone metabolite.

However, Applicants respectfully submit that a single search would encompass all of the claims as currently presented, as all of them recite a ziprasidone